eccogene glp-1 Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China Oral GLP-1-Based Therapeutics in the
Pay in 4 interest-free payments of $6.95 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20








:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)



















